Frunevetmab

Last updated

Frunevetmab
Monoclonal antibody
Type Whole antibody
Source Rat
Target Nerve growth factor (NGF)
Clinical data
Trade names Solensia
License data
Routes of
administration
Subcutaneous
ATCvet code
Legal status
Legal status
Identifiers
CAS Number
UNII
KEGG

Frunevetmab, sold under the brand name Solensia, is a medication used to treat pain associated with osteoarthritis in cats. [2]

Contents

It is the first monoclonal antibody new animal drug approved by the U.S. Food and Drug Administration (FDA) for use in any animal species. [2]

Frunevetmab is the international nonproprietary name (INN). [4]

Clinical usage

Frunevetmab is a cat-specific monoclonal antibody (a type of protein) designed to recognize and attach to a protein called nerve growth factor (NGF) that is involved in the regulation of pain. [2] When frunevetmab binds to NGF, it prevents the pain signal from reaching the brain. [2]

Frunevetmab is indicated for the alleviation of pain associated with osteoarthritis in cats. [2] [3]

The most common side effects seen in cats include vomiting, diarrhea, injection site pain, scabbing on the head and neck, dermatitis, and pruritus (itchy skin). [2]

History

In February 2021, Frunevetmab was approved for medical use in the European Union. [3]

In January 2022, the following year, Frunevetmab was approved for medical use in the United States. [2] [5]

Development as a potential drug for humans was stopped due to risk concerns over worsening osteoarthritis. [6]

See also

Related Research Articles

<span class="mw-page-title-main">Tremelimumab</span>

Tremelimumab, sold under the brand name Imjudo, is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma. Tremelimumab is designed to attach to and block CTLA-4, a protein that controls the activity of T cells, which are part of the immune system.

Ocrelizumab, sold under the brand name Ocrevus, is a medication used for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and is an immunosuppressive drug. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.

Tanezumab is a monoclonal antibody against nerve growth factor as a treatment for pain via a novel mechanisms different from conventional pain-killer drugs. Tanezumab was discovered and developed by Rinat Neuroscience and was acquired by Pfizer in 2006.

<span class="mw-page-title-main">Tralokinumab</span>

Tralokinumab sold under the brand names Adtralza (EU/UK) and Adbry (US) among others, is a human monoclonal antibody used for the treatment of atopic dermatitis. Tralokinumab targets the cytokine interleukin 13.

Alirocumab, sold under the brand name Praluent, is a medication used as a second-line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment. It is a human monoclonal antibody that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety.

Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate used for the treatment of urothelial cancer. It is a nectin-4-directed antibody and microtubule inhibitor conjugate. Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker.

Inebilizumab, sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults. Inebilizumab is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells.

<span class="mw-page-title-main">Galcanezumab</span> Monoclonal antibody

Galcanezumab, sold under the brand name Emgality, is a humanized monoclonal antibody used for the prevention of migraine. It is also used for cluster headaches.

Burosumab, sold under the brand name Crysvita, is a human monoclonal antibody medication approved 2018 for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia.

Ravulizumab, sold under the brand name Ultomiris, is a humanized monoclonal antibody complement inhibitor medication designed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome. It is designed to bind to and prevent the activation of Complement component 5 (C5).

Satralizumab, sold under the brand name Enspryng, is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. The drug is being developed by Chugai Pharmaceutical, a subsidiary of Roche.

Sutimlimab, sold under the brand name Enjaymo, is a monoclonal antibody that is used to treat adults with cold agglutinin disease (CAD). It is given by intravenous infusion. Sutimlimab prevents complement-enhanced activation of autoimmune human B cells in vitro.

Bamlanivimab is a monoclonal antibody developed by AbCellera Biologics and Eli Lilly as a treatment for COVID-19. The medication was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in November 2020, and the EUA was revoked in April 2021.

Nerve growth factor (NGF) inhibitors are a class of compounds that inhibit the action of the neurotrophin nerve growth factor by targeting NGF molecules or NGF receptors. NGF inhibitors have demonstrated therapeutic potential in treatment of certain chronic pain disorders, including osteoarthritis, and chronic lower back pain. Two NGF inhibitors are undergoing clinical trials as potential treatments for pain disorders.

Bebtelovimab is a monoclonal antibody developed by AbCellera and Eli Lilly as a treatment for COVID-19.

Teclistamab, sold under the brand name Tecvayli, is a human bispecific monoclonal antibody used for the treatment of relapsed and refractory multiple myeloma. It is a bispecific antibody that targets the CD3 receptor expressed on the surface of T-cells and B-cell maturation antigen (BCMA), which is expressed on the surface of malignant multiple myeloma B-lineage cells.

Bedinvetmab, sold under the brand name Librela is a canine monoclonal antibody used for the control of pain associated with osteoarthritis in dogs. Librela is sponsored by Zoetis.

Epcoritamab, sold under the brand name Epkinly, is a monoclonal antibody anticancer medication used for the treatment of diffuse large B-cell lymphoma. Epcoritamab is a bispecific CD20-directed CD3 T-cell engager.

References

  1. "NADA 141-546 Solensia™ frunevetmab injection Injectable Solution Cats". animaldrugsatfda.fda.gov. Archived from the original on 15 January 2022.[ bare URL PDF ]
  2. 1 2 3 4 5 6 7 8 "FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species". U.S. Food and Drug Administration (FDA) (Press release). 13 January 2022. Archived from the original on 13 January 2022. Retrieved 14 January 2022.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  3. 1 2 3 "Solensia EPAR". European Medicines Agency (EMA). 11 December 2020. Archived from the original on 15 January 2022. Retrieved 14 January 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3). hdl: 10665/330961 .
  5. "Zoetis Announces FDA Approval of Solensia (frunevetmab injection) to Control Osteoarthritis Pain in Cats". Zoetis. 13 January 2022. Archived from the original on 13 January 2022. Retrieved 14 January 2022.
  6. https://www.painnewsnetwork.org/stories/2022/1/14/fda-approves-pain-reliever-for-cats-considered-too-risky-for-humans.{{cite web}}: Missing or empty |title= (help)

PD-icon.svg This article incorporates public domain material from the United States Department of Health and Human Services.

Bibliography